Clinical trials: Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
ZR-CHOP in DLBCL With Specific Gene Abnormality
This is a phase 2, single center clinical trial. to evaluating the efficacy and safety of Zanubrutinib in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma with specific gene abnormality.
- Trial name
- NCT05290337
- Testing
- zanubrutinib
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Fudan University
Leukemia, Lymphoma
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00062296
- Testing
- rituximab, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fox Chase Cancer Center
Lymphoma, Large B-Cell, Diffuse
Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel
The aim of this non-interventional multi-center study is to evaluate quality of life (QOL) and other patient reported outcomes (PROs) among adults with diffuse large b-cell lymphoma (DLBCL) following Chimeric Antigen Receptor…
- Trial name
- NCT05199961
- Testing
- Digital Health Coaching
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pack Health
Relapsed or Refractory B-cell Lymphoma
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
To evaluate the efficacy and safety of selinexor combined with R-GDP regimen in the treatment of patients with TP53-altered relapsed or refractory B-cell lymphoma.
- Trial name
- NCT06062641
- Testing
- SR-GDP
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Diffuse, Large B-Cell, Lymphoma
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
The purpose of this study is to comparing the Efficacy and Safety between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients.
- Trial name
- NCT02867566
- Testing
- IBI301 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hypogonadism
Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality
This study is a prospective non-randomised open label multicenter phase two study in male long-term survivors of malignant lymphoma including Hodgkin Lymphoma (HL) and Diffuse Large B-Cell Lymphoma (DLBCL).
- Trial name
- Vitality (NCT04492553)
- Testing
- AndroGel
- Where
- 3 sites in Denmark
- Volunteers
- 7 people
- Sponsor
- Lars Møller Pedersen
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
B-cell Lymphomas
Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas
Currently, a majority of B cell lymphomas cannot be cured by standard chemo-radiotherapy. Most B cell lymphomas express cluster of differentiation antigen 19 (CD19), which represents a very attractive target for chimeric antigen…
- Trial name
- 4SCAR19273 (NCT02247609)
- Testing
- Anti-CD19 CAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University
Relapsed/Refractory Large B-cell Lymphoma
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
The primary objectives of this study are: Phase 1: To evaluate the safety of axicabtagene ciloleucel in combination with utomilumab and to identify the most appropriate dose and timing of utomilumab to carry forward into Phase 2…
- Trial name
- ZUMA-11 (NCT03704298)
- Testing
- Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Kite, A Gilead Company
Non-Hodgkin's Lymphoma
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary…
- Trial name
- NCT06667687
- Testing
- ABBV-291
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 21 people
- Sponsor
- AbbVie
Relapsed Advanced Lymphomas
A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
- Trial name
- ASHA-1 (NCT05984147)
- Testing
- AUR108
- Where
- 27 sites in India
- Volunteers
- 40 people
- Sponsor
- Aurigene Discovery Technologies Limited
Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.
- Conditions
- Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04305444
- Testing
- DTRM-555
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Zhejiang DTRM Biopharma
Non-Hodgkin's Lymphoma
Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma
The purpose of this study is to provide data on the safety and efficacy of pegfilgrastim when administered on the same day versus the next day of chemotherapy, as measured by the duration of grade 4 neutropenia.
- Trial name
- NCT00115193
- Testing
- pegfilgrastim
- Volunteers
- 77 people
- Sponsor
- Amgen
Chronic Myeloproliferative Disorders, Leukemia
Treatment for Chronic Pain in Patients With Advanced Cancer
RATIONALE: Different drug formulations and combinations of drugs may help patients with chronic pain live more comfortably. It is not yet known which regimen is most effective for chronic pain.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003687
- Testing
- dextromethorphan hydrobromide, morphine sulfate
- Where
- 4 sites in Canada
- Volunteers
- 87 people
- Sponsor
- NCIC Clinical Trials Group
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Prospective, multicenter, open label, phase II randomized clinical trial in DLBCL patients relapsed or refractory to first line R-chemo, aged 18-70 years and candidate to autologous transplant.
- Trial name
- FIL_POLARDHAP (NCT05966233)
- Testing
- R-DHAP, Pola-R-DHAP
- Where
- 37 sites in Italy
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lymphoma
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Determination of genetic markers for aggressive non-Hodgkin's lymphoma may help identify patients with this disease and help predict the outcome of treatment.
- Trial name
- NCT00003863
- Testing
- comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization
- Where
- 69 sites in United States
- Volunteers
- 391 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma, Large B-Cell, Diffuse
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
This Phase I clinical trial studies the side effects and maximum tolerated dose (MTD) of the combination of brentuximab vedotin (BV) and lenalidomide in the treatment of patients with relapsed or refractory diffuse large B-cell…
- Trial name
- NCT02086604
- Testing
- Brentuximab vedotin, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Washington University School of Medicine
Renal Cancer, Renal Clear Cell Carcinoma
CD70-targeted immunoPET Imaging of Malignant Cancers
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma…
- Conditions
- Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT06852638
- Testing
- [18F]F-RESCA-RCCB6, [18F]F-RESCA-R8B4, [68Ga]Ga-NOTA-R8B4
- Where
- China
- Volunteers
- 300 people
- Sponsor
- RenJi Hospital
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced or…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049699
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Diffuse Large B-Cell Lymphoma (DLBCL)
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Efficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in elderly patients with newly diagnosed MYC/BCL2 double-expressor DLBCL.
- Trial name
- NCT07493148
- Testing
- Chidamide, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ou Bai, MD/PHD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.